Discover
Tremfya (guselkumab) / J&JJanssen submits application to U.S. FDA seeking first-in-class approval of Tremfya (guselkumab) for treatment of adults with active psoriatic arthritis (PRNewswire) - Sep 16, 2019 - "The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking first-in-class approval of TREMFYA (guselkumab) for the treatment of adult patients with active psoriatic arthritis (PsA)....Janssen also expects to submit a marketing application to the European Medicines Agency seeking approval of TREMFYA as a treatment for PsA before the end of the year."Taltz (ixekizumab) / Eli LillyTaltz pricing: Wholesale acquisition cost of $5,162/Injection (J.P. Morgan) - Sep 20, 2019 - A subscription to Thomson ONE is required to gain full access to report 67963077; Page no: 20; REPORT TITLE: "European Pharmaceuticals: Weekly Chartbook: trx for week ending September 6th”; AUTHOR: Vosser, Richard, et al; DATE: 09/15/2019Tremfya (guselkumab) / J&JTremfya pricing: Wholesale acquisition cost of $10,859/Injection (J.P. Morgan) - Sep 20, 2019 - A subscription to Thomson ONE is required to gain full access to report 67963077; Page no: 20; REPORT TITLE: "European Pharmaceuticals: Weekly Chartbook: trx for week ending September 6th”; AUTHOR: Vosser, Richard, et al; DATE: 09/15/2019Cosentyx (secukinumab) / NovartisCosentyx pricing: Wholesale acquisition cost of $5,179/Injection (J.P. Morgan) - Sep 20, 2019 - A subscription to Thomson ONE is required to gain full access to report 67963077; Page no: 20; REPORT TITLE: "European Pharmaceuticals: Weekly Chartbook: trx for week ending September 6th”; AUTHOR: Vosser, Richard, et al; DATE: 09/15/2019Skyrizi (risankizumab) / AbbVie, Boehringer IngelheimSkyrizi sales projection: $250M in 2019, $850M in 2020 and $3B in 2024 (Cowen & Co) - Sep 23, 2019 - A subscription to Thomson ONE is required to gain full access to report 67971845; Page no: 491; REPORT TITLE: "Therapeutic categories outlook”; AUTHOR: Cowen Health Care Research, et al; DATE: 09/17/2019Tremfya (guselkumab) / J&JTremfya WW sales projection: >$2.5B in 2024 (Cowen & Co) - Sep 23, 2019 - A subscription to Thomson ONE is required to gain full access to report 67971845; Page no: 481; REPORT TITLE: "Therapeutic categories outlook”; AUTHOR: Cowen Health Care Research, et al; DATE: 09/17/2019Taltz (ixekizumab) / Eli LillyTaltz sales projection: $1.38B in 2019, $1.93B in 2020 and $3.1B in 2024 (Cowen & Co) - Sep 23, 2019 - A subscription to Thomson ONE is required to gain full access to report 67971845; Page no: 484; REPORT TITLE: "Therapeutic categories outlook”; AUTHOR: Cowen Health Care Research, et al; DATE: 09/17/2019Cosentyx (secukinumab) / NovartisCosentyx sales projection: $3.27B in 2019, $3.59B in 2020 and $5.1B in 2024 (Cowen & Co) - Sep 23, 2019 - A subscription to Thomson ONE is required to gain full access to report 67971845; Page no: 487; REPORT TITLE: "Therapeutic categories outlook”; AUTHOR: Cowen Health Care Research, et al; DATE: 09/17/2019Stelara (ustekinumab) / J&JStelara WW sales projection: $9B in 2024 (Cowen & Co) - Sep 23, 2019 - A subscription to Thomson ONE is required to gain full access to report 67971845; Page no: 479; REPORT TITLE: "Therapeutic categories outlook”; AUTHOR: Cowen Health Care Research, et al; DATE: 09/17/2019
